Literature DB >> 25193959

Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.

Christopher P Venner1, Julian D Gillmore2, Sajitha Sachchithanantham2, Shameem Mahmood2, Thirusha Lane2, Darren Foard2, Murielle Roussel3, Lisa Rannigan2, Simon Dj Gibbs4, Jennifer H Pinney2, Carol J Whelan2, Helen J Lachmann2, Philip N Hawkins2, Ashutosh D Wechalekar5.   

Abstract

Entities:  

Keywords:  amyloidosis; patient selection; stem cell transplantation

Mesh：

Substances：

Year:  2014        PMID： 25193959      PMCID： PMC4258758          DOI： 10.3324/haematol.2014.108191

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  26 in total

1.  Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study.

Authors:  Philippe Moreau; Arnaud Jaccard; Lotfi Benboubker; Bruno Royer; Xavier Leleu; Franck Bridoux; Gilles Salles; Veronique Leblond; Murielle Roussel; May Alakl; Olivier Hermine; Lucie Planche; Jean-Luc Harousseau; Jean-Paul Fermand
Journal:  Blood       Date:  2010-08-19       Impact factor: 22.113

2.  Trend toward improved day 100 and two-year survival following stem cell transplantation for AL: a comparison before and after 2006.

Authors:  M A Gertz; M Q Lacy; A Dispenzieri; S Kumar; S R Hayman; F Buadi; D Dingli; N Leung; W J Hogan
Journal:  Amyloid       Date:  2011-06       Impact factor: 7.141

3.  Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis.

Authors:  Amit Fadia; Liam F Casserly; Vaishali Sanchorawala; David C Seldin; Daniel G Wright; Martha Skinner; Laura M Dember
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

4.  The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.

Authors:  Jennifer M Bird; Rhian Fuge; Bhawna Sirohi; Jane F Apperley; Ann Hunter; John Snowden; Premini Mahendra; Donald Milligan; Jenny Byrne; Timothy Littlewood; Christopher Fegan; Grant McQuaker; Antonio Pagliuca; Peter Johnson; Amin Rahemtulla; Curly Morris; David I Marks
Journal:  Br J Haematol       Date:  2006-07-05       Impact factor: 6.998

5.  Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006.

Authors:  M A Gertz; M Q Lacy; A Dispenzieri; S K Kumar; F K Buadi; D Dingli; N Leung; W J Hogan; S R Hayman
Journal:  Bone Marrow Transplant       Date:  2010-10-11       Impact factor: 5.483

6.  Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.

Authors:  Shameem Mahmood; Christopher P Venner; Sajitha Sachchithanantham; Thirusha Lane; Lisa Rannigan; Darren Foard; Jenny H Pinney; Simon D J Gibbs; Carol J Whelan; Helen J Lachmann; Julian D Gillmore; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Br J Haematol       Date:  2014-06-13       Impact factor: 6.998

7.  High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

Authors:  Arnaud Jaccard; Philippe Moreau; Veronique Leblond; Xavier Leleu; Lotfi Benboubker; Olivier Hermine; Christian Recher; Bouchra Asli; Bruno Lioure; Bruno Royer; Fabrice Jardin; Frank Bridoux; Bernard Grosbois; Jérome Jaubert; Jean-Charles Piette; Pierre Ronco; Fabrice Quet; Michel Cogne; Jean-Paul Fermand
Journal:  N Engl J Med       Date:  2007-09-13       Impact factor: 91.245

8.  Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.

Authors:  Nelson Leung; Angela Dispenzieri; Martha Q Lacy; Shaji K Kumar; Suzanne R Hayman; Fernando C Fervenza; Stephen S Cha; Morie A Gertz
Journal:  Clin J Am Soc Nephrol       Date:  2007-04-04       Impact factor: 8.237

9.  Outcome of autologous stem cell transplantation for AL amyloidosis in the UK.

Authors:  Hugh J B Goodman; Julian D Gillmore; Helen J Lachmann; Ashutosh D Wechalekar; Arthur R Bradwell; Philip N Hawkins
Journal:  Br J Haematol       Date:  2006-07-05       Impact factor: 6.998

10.  Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis.

Authors:  Ashutosh D Wechalekar; Hugh J B Goodman; Helen J Lachmann; Mark Offer; Philip N Hawkins; Julian D Gillmore
Journal:  Blood       Date:  2006-09-21       Impact factor: 22.113
View more
  6 in total

Review 1.  Stem Cell Mobilization and Autologous Transplant for Immunoglobulin Light-Chain Amyloidosis.

Authors:  Morie A Gertz; Stefan Schonland
Journal:  Hematol Oncol Clin North Am       Date:  2020-09-12       Impact factor: 3.722

Review 2.  AL amyloidosis: untangling new therapies.

Authors:  Susan Bal; Heather Landau
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation.

Authors:  Anita D'Souza; Jiaxing Huang; Parameswaran Hari
Journal:  Biol Blood Marrow Transplant       Date:  2015-12-29       Impact factor: 5.742

4.  Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.

Authors:  Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Francis K Buadi; David Dingli; Suzanne R Hayman; Shaji K Kumar; Nelson Leung; John Lust; S Vincent Rajkumar; Stephen J Russell; Vera J Suman; Jennifer G Le-Rademacher; William J Hogan
Journal:  Cancer       Date:  2016-05-03       Impact factor: 6.860

Review 5.  Update on treatment of light chain amyloidosis.

Authors:  Shameem Mahmood; Giovanni Palladini; Vaishali Sanchorawala; Ashutosh Wechalekar
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

6.  Deferred autologous stem cell transplantation in systemic AL amyloidosis.

Authors:  Richa Manwani; Ute Hegenbart; Shameem Mahmood; Sajitha Sachchithanantham; Charalampia Kyriakou; Kwee Yong; Rakesh Popat; Neil Rabin; Carol Whelan; Tobias Dittrich; Christoph Kimmich; Philip Hawkins; Stefan Schönland; Ashutosh Wechalekar
Journal:  Blood Cancer J       Date:  2018-11-05       Impact factor: 11.037
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.